Cancer Gene Therapy Market - Global Forecast 2025-2032

Cancer gene therapy is reshaping oncology, offering targeted interventions and broadening treatment pathways for complex cancers. Senior decision-makers face an increasingly sophisticated landscape in this field, marked by scientific breakthroughs, evolving regulatory standards, and shifting global investment trends.

Market Snapshot: Cancer Gene Therapy Market Size and Growth Outlook

The Cancer Gene Therapy Market is on a dynamic growth trajectory, currently valued at USD 2.75 billion in 2024 and anticipated to reach USD 3.30 billion in 2025. With a sustained CAGR of 19.94%, market value could total USD 11.81 billion by 2032. This expansion is propelled by advances in genetic engineering methods, the increasing acceptance of tailored treatments in oncology, and cross-border capital flows supporting research and commercialization. Leading industry participants and new entrants are responding to regulatory harmonization and clinical innovation, shaping a competitive business environment with evolving business models and intensified market activity.

Cancer Gene Therapy Market Scope & Segmentation

This report offers a targeted analysis for leaders aiming to capture opportunities in cancer gene therapy. It details how various technologies, therapies, regions, and stakeholders drive market strategies and commercial potential.

• Vector Type: Evaluates nonviral platforms such as lipid nanoparticles, physical and polymeric techniques, as well as viral approaches—including adeno-associated, adenoviral, lentiviral, and retroviral systems—to address diverse requirements in gene delivery and disease targeting.
• Therapy Type: Reviews ex vivo and in vivo gene therapy methodologies, highlighting their impact on production complexity, regulatory frameworks, and adoption models across clinical settings.
• Indication: Analyzes therapies for hematological malignancies like leukemia, lymphoma, and myeloma alongside solid tumor applications, including breast, lung, colorectal, and prostate cancers, reflecting evolving clinical priorities and patient-centered strategies.
• Stage: Provides an overview of candidate therapies in development, from preclinical through late-stage clinical trials and commercialization, outlining key innovation pipelines and the progress of market-ready products.
• End User: Investigates usage patterns across hospitals, clinics, oncology centers, and research facilities, pinpointing where adoption is accelerating and where operational efficiencies are being realized.
• Regions Covered: Surveys the Americas, Europe, Middle East & Africa, and Asia-Pacific, examining local drivers, policy trends, and unique barriers or opportunities influencing regional uptake.
• Key Companies Analyzed: Profiles the strategies and market activities of leading organizations such as Gilead Sciences, Novartis AG, Bristol-Myers Squibb, Amgen, bluebird bio, Adaptimmune Therapeutics, Cellectis, uniQure, Transgene SA, and Sorrento Therapeutics to benchmark performance and partnership options.

Key Takeaways: Strategic Imperatives and Industry Trends

• Precision genome editing and the deployment of advanced vector systems are setting new standards in oncology care and therapy innovation.
• Intensive cooperation among pharmaceutical companies, research institutions, and manufacturing partners is improving the efficiency of clinical development in regulatory-adaptive environments.
• Solid tumor gene therapies are advancing rapidly due to enhanced drug delivery technologies, while therapies for blood cancers continue to anchor early clinical research and adoption efforts.
• Asia-Pacific is emerging as a key region for clinical adoption and global trial expansion, supported by improving healthcare infrastructure and progressive regulatory policies.
• Real-world evidence platforms and adaptive clinical trial models are supporting faster therapy development, providing flexibility for market entry and evidence generation.
• Operational agility and resilient supply chains are becoming strategic advantages, especially for adapting to emerging clinical scenarios and evolving market demands.

Tariff Impact: Effects of 2025 United States Trade Measures

Recent U.S. tariff policy has raised costs for components and raw materials in gene therapy production, primarily when sourced internationally. Companies are responding through supply chain shifts, increased domestic manufacturing, and consideration of alternative delivery solutions. Regulatory agencies are also supporting industry resilience through oversight and flexible approaches to modular manufacturing, contributing to increased sector robustness.

Methodology & Data Sources

This research combines structured expert interviews, executive insights, regulatory reviews, analyses of clinical trial and scientific databases, and financial disclosures. Triangulating these credible sources ensures reliable, consistent conclusions for both qualitative assessment and quantitative validation.

Why This Report Matters for Senior Decision-Makers

• Highlights market drivers, technology trajectories, and critical segment trends to inform strategic cancer gene therapy decisions.
• Delivers actionable guidance to manage partnerships, address supply chain challenges, and refine go-to-market strategies amid evolving industry conditions.
• Enables leaders to invest confidently and expand, supported by validated forecasts and evidence-based recommendations aligned with regulatory realities.

Conclusion

The landscape for cancer gene therapy is rapidly evolving, creating new avenues for clinical application and commercial growth. This report supports informed planning and strategic positioning within a complex and advancing oncology market.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.